Cerebral microbleeds
Conditions
Interventions
Treatment group:On the basis of Western medicine treatment, ginkgo biloba ketone ester tablets (ingredient: ginkgo biloba ketone ester, specification: 0.25g/tablet, 12 tablets/box, manufacturer: Shang
control group:The control group received basic Western medicine treatment for 48 weeks.
Sponsors
Shanghai Municipal Health Commission
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) According to the diagnostic criteria of the Chinese Consensus on the Diagnosis and Treatment of Small Vascular Diseases (2021 Edition) , it was diagnosed as cerebral microbleeds and confirmed through cranial SWI; (2) Age>= 60 years and < = 85 years, gender is not limited; (3) Number of cerebral microbleeds <= 40; (4) Stable vital signs, clear consciousness, and the ability to cooperate with examinations and treatments; (5) Those who are willing to participate in this experiment and sign an informed consent form.
Exclusion criteria
Exclusion criteria: Those who meet one of the following conditions cannot be included in this study: (1) Contraindications for MRI examination include implantation of pacemakers and nerve stimulators inside the body, uncontrolled epilepsy, and patients with claustrophobia; (2) Existence of consciousness disorders or mental illnesses; (3) Combined with severe coagulation dysfunction, malignant tumors, severe infections, as well as digestive system diseases, liver and kidney, cardiovascular and cerebrovascular diseases; (4) Pregnant or lactating women; (5) Patients who are allergic to the medication used.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of cerebral microbleeds; | — |
Secondary
| Measure | Time frame |
|---|---|
| Activities of Daily Living Scale;Montreal Cognitive Assessment Scale;Clinical Dementia Rating Scale; | — |
Countries
China
Contacts
Public ContactZhu Xuying
Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital
Outcome results
None listed